

Urogenital/Anogenital (UG/AG) Panels

Policy Number: MMP373.30
Last Committee Approval Date: September 11, 2024
Effective Date: October 1, 2024

[Instructions for Use](#)

Table of Contents	Page
Coverage Rationale	1
Applicable Codes	2
Definitions	4
CMS Related Documents	4
Clinical Evidence	6
References	9
Policy History/Revision Information	9
Instructions for Use	10

Related Medicare Advantage Medical Policies
<ul style="list-style-type: none"> Clinical Diagnostic Laboratory Services Molecular Pathology/Molecular Diagnostics/Genetic Testing (Coverage Summary) Molecular Pathology/Molecular Diagnostics/Genetic Testing (Policy Guideline)

Related Medicare Advantage Reimbursement Policies
<ul style="list-style-type: none"> Clinical Laboratory Improvement Amendments (CLIA) ID Requirement Policy, Professional Laboratory Services Policy, Professional Molecular Pathology Policy, Professional and Facility

Coverage Rationale

Overview

Molecular Panel tests for infectious diseases have changed the landscape of clinical microbiology. They play an important role in diagnostic testing, as they simultaneously detect several different pathogens associated with similar and overlapping clinical symptomatology. For this reason, they are also known as 'Syndromic Panel' tests. These Panels belong to a category of testing known as culture-independent diagnostic tests (CIDTs), which are tests that detect pathogens without the need to grow and isolate them in culture. These tests have shorter turnaround times, often have good test performance characteristics, and require limited technical expertise, making them appealing for use by clinicians as well as clinical laboratories.

CMS National Coverage Determinations (NCDs)

Medicare does not have an NCD for Urogenital/Anogenital (UG/AG) Panels.

CMS Local Coverage Determinations (LCDs) and Articles

Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs) exist and compliance with these policies is required where applicable. For specific LCDs/LCAs, refer to the table for [Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing](#).

For coverage guidelines for states/territories with no LCDs/LCAs:

- For the UG/AG Panels, epidemiologic indication or potential exposure to sexually transmitted pathogens (i.e., in the case of clinical concern for multiple sexually transmitted infections (STIs) due to a high-risk experience) is considered reasonable and necessary even in the absence of clinical symptoms. The high-risk reason for Panel testing must clearly be documented.
- In the absence of a high-risk experience, if the primary clinical concern is for a few specific pathogens due to specific signs and symptoms (i.e., lesions suggestive of herpes simplex virus [HSV]), then it is expected that only a small targeted Panel (i.e., including HSV-1 and HSV-2) will be performed. In such cases, expanded Panels are NOT considered reasonable and necessary and will NOT be covered.
- For the diagnosis of infectious vaginosis/vaginitis, it is reasonable and necessary to perform a (targeted or expanded) Panel that includes a combination of at least 2 of the following: Gardnerella vaginalis, other bacterial vaginosis (BV)-

associated bacteria (BVAB) (such as Atopobium vaginae and/or Megasphaera types), Trichomonas vaginalis, and Candida species.

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service; however, language may be included in the listing below to indicate if a code is non-covered. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

CPT Code	Description
0352U	Infectious disease (bacterial vaginosis and vaginitis), multiplex amplified probe technique, for detection of bacterial vaginosis-associated bacteria (BVAB-2, Atopobium vaginae, and Megasphaera type 1), algorithm reported as detected or not detected and separate detection of Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, and trichomonas vaginalis, vaginal-fluid specimen, each result reported as detected or not detected (Effective 10/01/2022)
81513	Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis
81514	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), and Lactobacillus species (L. crispatus and L. jensenii), utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis, includes separate detection of Trichomonas vaginalis and/or Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata, Candida krusei, when reported

CPT® is a registered trademark of the American Medical Association

Diagnosis Code	Description
A51.0	Primary genital syphilis
A51.1	Primary anal syphilis
A51.31	Condyloma latum
A52.76	Other genitourinary symptomatic late syphilis
A54.00	Gonococcal infection of lower genitourinary tract, unspecified
A54.01	Gonococcal cystitis and urethritis, unspecified
A54.02	Gonococcal vulvovaginitis, unspecified
A54.03	Gonococcal cervicitis, unspecified
A54.09	Other gonococcal infection of lower genitourinary tract
A54.1	Gonococcal infection of lower genitourinary tract with periurethral and accessory gland abscess
A54.21	Gonococcal infection of kidney and ureter
A54.22	Gonococcal prostatitis
A54.23	Gonococcal infection of other male genital organs
A54.24	Gonococcal female pelvic inflammatory disease
A54.29	Other gonococcal genitourinary infections
A54.6	Gonococcal infection of anus and rectum
A56.00	Chlamydial infection of lower genitourinary tract, unspecified
A56.01	Chlamydial cystitis and urethritis
A56.02	Chlamydial vulvovaginitis
A56.09	Other chlamydial infection of lower genitourinary tract

Diagnosis Code	Description
A56.11	Chlamydial female pelvic inflammatory disease
A56.19	Other chlamydial genitourinary infection
A56.2	Chlamydial infection of genitourinary tract, unspecified
A56.3	Chlamydial infection of anus and rectum
A59.00	Urogenital trichomoniasis, unspecified
A59.01	Trichomonal vulvovaginitis
A59.02	Trichomonal prostatitis
A59.03	Trichomonal cystitis and urethritis
A59.09	Other urogenital trichomoniasis
A60.00	Herpesviral infection of urogenital system, unspecified
A60.01	Herpesviral infection of penis
A60.02	Herpesviral infection of other male genital organs
A60.03	Herpesviral cervicitis
A60.04	Herpesviral vulvovaginitis
A60.09	Herpesviral infection of other urogenital tract
A60.1	Herpesviral infection of perianal skin and rectum
A60.9	Anogenital herpesviral infection, unspecified
A63.0	Anogenital (venereal) warts
B20	Human immunodeficiency virus [HIV] disease
B37.31	Acute candidiasis of vulva and vagina
B37.32	Chronic candidiasis of vulva and vagina
B37.41	Candidal cystitis and urethritis
B37.42	Candidal balanitis
B37.49	Other urogenital candidiasis
B37.89	Other sites of candidiasis
B97.35	Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere
D26.0	Other benign neoplasm of cervix uteri
L29.2	Pruritus vulvae
L29.3	Anogenital pruritus, unspecified
N34.1	Nonspecific urethritis
N34.2	Other urethritis
N41.0	Acute prostatitis
N41.3	Prostatocystitis
N48.5	Ulcer of penis
N76.0	Acute vaginitis
N76.1	Subacute and chronic vaginitis
N76.2	Acute vulvitis
N76.3	Subacute and chronic vulvitis
N76.5	Ulceration of vagina
N76.6	Ulceration of vulva
N76.82	Fournier disease of vagina and vulva
N76.89	Other specified inflammation of vagina and vulva
N77.1	Vaginitis, vulvitis and vulvovaginitis in diseases classified elsewhere
N89.8	Other specified noninflammatory disorders of vagina
N90.89	Other specified noninflammatory disorders of vulva and perineum

Diagnosis Code	Description
N93.0	Postcoital and contact bleeding
N93.8	Other specified abnormal uterine and vaginal bleeding
O98.711	Human immunodeficiency virus [HIV] disease complicating pregnancy, first trimester
O98.712	Human immunodeficiency virus [HIV] disease complicating pregnancy, second trimester
O98.713	Human immunodeficiency virus [HIV] disease complicating pregnancy, third trimester
R10.2	Pelvic and perineal pain
R30.0	Dysuria
T74.21XA	Adult sexual abuse, confirmed, initial encounter
T74.21XD	Adult sexual abuse, confirmed, subsequent encounter
T74.21XS	Adult sexual abuse, confirmed, sequela
T74.51XA	Adult forced sexual exploitation, confirmed, initial encounter
T74.51XD	Adult forced sexual exploitation, confirmed, subsequent encounter
T74.51XS	Adult forced sexual exploitation, confirmed, sequela
T76.21XA	Adult sexual abuse, suspected, initial encounter
T76.21XD	Adult sexual abuse, suspected, subsequent encounter
T76.21XS	Adult sexual abuse, suspected, sequela
T76.51XA	Adult forced sexual exploitation, suspected, initial encounter
T76.51XD	Adult forced sexual exploitation, suspected, subsequent encounter
T76.51XS	Adult forced sexual exploitation, suspected, sequela
Z04.41	Encounter for examination and observation following alleged adult rape
Z04.71	Encounter for examination and observation following alleged adult physical abuse
Z04.81	Encounter for examination and observation of victim following forced sexual exploitation
Z11.3	Encounter for screening for infections with a predominantly sexual mode of transmission
Z20.2	Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission
Z20.6	Contact with and (suspected) exposure to human immunodeficiency virus [HIV]
Z21	Asymptomatic human immunodeficiency virus [HIV] infection status
Z33.1	Pregnant state, incidental
Z33.3	Pregnant state, gestational carrier
Z72.51	High risk heterosexual behavior
Z72.52	High risk homosexual behavior
Z72.53	High risk bisexual behavior
Z72.89	Other problems related to lifestyle

Definitions

Panel: A test that detects > 1 pathogen.

Syndromic Panel: A test that simultaneously detects multiple different pathogens associated with similar and overlapping clinical symptomatology.

Centers for Medicare and Medicaid Services (CMS) Related Documents

After checking the table below and searching the [Medicare Coverage Database](#), if no NCD, LCD or LCA is found refer to the criteria as noted in the [Coverage Rationale](#) section above.

NCD	LCD	LCA	Contractor Type	Contractor Name
Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing				
N/A	L39038 MoIDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing	A58747 Billing and Coding: MoIDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing	Part A and B MAC	CGS
N/A	L39001 MoIDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing	A58720 Billing and Coding: MoIDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing	Part A and B MAC	Noridian
N/A	L39003 MoIDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing	A58726 Billing and Coding: MoIDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing	Part A and B MAC	Noridian
N/A	L38988 MoIDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing	A58710 Billing and Coding: MoIDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing	Part A and B MAC	Palmetto**
N/A	L39044 MoIDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing	A58761 Billing and Coding: MoIDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing	Part A and B MAC	WPS*

Medicare Administrative Contractor (MAC) With Corresponding States/Territories	
MAC Name (Abbreviation)	States/Territories
CGS Administrators, LLC (CGS)	KY, OH
First Coast Service Options, Inc. (First Coast)	FL, PR, VI
National Government Services, Inc. (NGS)	CT, IL, ME, MA, MN, NH, NY, RI, VT, WI
Noridian Healthcare Solutions, LLC (Noridian)	AS, AK, AZ, CA, GU, HI, ID, MT, NV, ND, Northern Mariana Islands, OR, SD, UT, WA, WY
Novitas Solutions, Inc. (Novitas)	AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX, VA**
Palmetto GBA (Palmetto)	AL, GA, NC, SC, TN, VA**, WV
Wisconsin Physicians Service Insurance Corporation (WPS)*	IA, IN, KS, MI, MO, NE
Notes	
*Wisconsin Physicians Service Insurance Corporation: Contract Number 05901 applies only to WPS Legacy Mutual of Omaha MAC A Providers.	
**For the state of Virginia: Part B services for the city of Alexandria and the counties of Arlington and Fairfax are excluded for the Palmetto GBA jurisdiction and included within the Novitas Solutions, Inc. jurisdiction.	

CMS Benefit Policy Manual

[Chapter 15: § 80.1-80.1.3 Clinical Laboratory Services](#)

CMS Claims Processing Manual

[Chapter 12; § 60 Payment for Pathology Services](#)

[Chapter 16; § 10.2 General Explanation of Payment; § 20 Calculation of Payment Rates-Clinical Laboratory Test Fee Schedules; § 40 Billing for Clinical Laboratory Tests](#)

Others

[CMS Lab NCDs - ICD-10; CMS.gov](#)

[Palmetto GBA MoIDx Website](#)

[Palmetto GBA MoIDx Manual, Palmetto GBA MoIDx Website](#)

L36021 Molecular Diagnostic Tests (MDT)

A56973 Billing and Coding: MoIDx: Molecular Diagnostic Tests (MDT)

L35160 MoIDx: Molecular Diagnostic Tests (MDT)

A57526 Billing and Coding: MoIDx: Molecular Diagnostic Tests (MDT)

L36256 MoIDx: Molecular Diagnostic Tests (MDT)

A57527 Billing and Coding: MoIDx: Molecular Diagnostic Tests (MDT)

L35025 MoIDx: Molecular Diagnostic Tests (MDT)

A56853 Billing and Coding: MoIDx: Molecular Diagnostic Tests (MDT)

L36807 MoIDx: Molecular Diagnostic Tests (MDT)

A57772 Billing and Coding: MoIDx: Molecular Diagnostic Tests (MDT)

L34519 Molecular Pathology Procedures

A58918 Billing and Coding: Molecular Pathology and Genetic Testing

L35062 Biomarkers Overview

A58917 Billing and Coding: Molecular Pathology and Genetic Testing

Clinical Evidence

Test Performance

In recent years, molecular syndromic panels have become routinely used for a number of infection types, including respiratory, gastrointestinal, central nervous system, bloodstream, and urogenital/anogenital. These panels provide rapid turnaround times for results and are often more sensitive than traditional testing for the various organisms included. However, test performance characteristics do vary depending on the specific panels and pathogens.

Molecular panel tests are also increasingly being used for the detection of urogenital and anogenital infections. The BD MAX™ vaginal panel has reported sensitivities and specificities of 89.8%/96.5%, 97.4%/96.8%, and 100%/100% for bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomoniasis (TV), respectively. In another study, the BD Affirm™ VPIII Microbial Identification Test showed a lower specificity of 81.6% for BV and lower sensitivity of 69.4% for VVC, while it performed equally well as the BD MAX™ for TV. These panels, however, have been shown to perform better than clinician assessment of vaginitis, for which many diagnoses remain empirical and for which guideline non-adherence is broad. Further, high rates of coinfection with STIs (24.4%-25.7%) have been observed. Panels detecting sexually transmitted pathogens have also become routine in clinical laboratories, as they provide a rapid result for organisms like Chlamydia species, that can be difficult to culture. Moreover, it is well-established that *N. gonorrhoeae* and *C. trachomatis* not only cause similar clinical syndromes but also coexist in a significant proportion of patients, highlighting the need for panel testing.

Schwebke et al. (2020) performed a prospective, multicenter clinical study to validate the performance of an in vitro diagnostic transcription-mediated NAATs for the diagnosis of BV, VVC, and TV. Clinician and patient obtained swab samples were collected from symptomatic women and were tested using the Aptima BV and Aptima Candida/Trichomonas vaginitis (CV/TV) assays. Results were compared to Nugent (plus Amsel for intermediate Nugent) scores for BV, Candida, and DNA sequencing for VVC, and a composite of NAAT and culture for TV. There were 1,519 subjects enrolled. Clinician collected samples for the investigational tests revealed a 95.0% sensitivity and 89.6% specificity for BV; a 91.7% sensitivity and 94.9% specificity for Candida; 84.7% sensitivity and 99.1 % specificity for *C. glabrata*; and a 96.5% sensitivity and 95.1% specificity for TV. Similar results were observed from the patient collected samples. Clinician diagnosis, in-clinic assessments and investigational assay results were compared with gold standard reference methods in a secondary assessment. This secondary assessment for BV resulted in a sensitivity of $\geq 96.2\%$ and specificity of $\geq 92.4\%$ for the investigational-assay samples compared to 83.4% and 85.5% for clinicians' diagnoses, 75.9% and 94.4% for original Amsel criteria, 81.1% and 90.1% for modified Amsel criteria, and $\leq 82.8\%$ and $\leq 91.1\%$ for any of the individual Amsel criterion components (vaginal pH, clue cells, and whiff test). For VVC due to the Candida species group or *C. glabrata*, sensitivity and specificity were $\geq 91.2\%$ and $\geq 98.9\%$, respectively for the investigational-assay samples compared to $\leq 27.9\%$ and $\leq 56.4\%$ for potassium hydroxide testing and $\leq 54.9\%$ and $\leq 85.5\%$ for

clinicians' diagnoses. For trichomoniasis, sensitivity was $\geq 96.4\%$ for the investigational-assay samples compared to 78.8% for culture and 38.1% for clinicians' diagnoses; specificity estimates were greater than 95% for all trichomoniasis detection methods. The authors reported that overall, the investigational tests revealed a higher sensitivity and specificity for detecting and diagnosing the causes of vaginitis compared to traditional methodologies for diagnosis. Study limitations included lack of diversity with regard to ethnic groups and high specificity of molecular testing, impacting sensitivity to disease attributable to minor species (e.g., *Prevotella*, *Candida krusei*), which were not included in assay design.

Thompson et al. (2020) conducted a comparative study to examine the performance of the BD Max Vaginal Panel (MAX VP) compared to BD Affirm VPIII (Affirm), noting Affirm to be the "standard of care". Four vaginal swabs were collected from each of 200 symptomatic participants. *Candida* culture, Gram stain and Nugent scoring and the Hologic Aptima *Trichomonas vaginalis* assay were used as part of the analysis. When at least two tests were positive for any vaginitis target, the results were considered true positive. Sensitivity and specificity of MAX VP for BV was 96.2% and 96.1%, respectively. For Affirm, sensitivity and specificity for BV were 96.2% and 81.6%, respectively. The sensitivity of MAX VP for *Candida* spp. was 98.4% and specificity was 95.4% whereas sensitivity for Affirm was 69.4% and specificity was 100%. Lastly, MAX VP and Affirm were 100% concordant in the detection of TV. The authors concluded that MAX VP showed better accuracy when compared to Affirm for detection of *Candida* spp. and BV, and the two tests were equally accurate for detection of TV. The study was limited by its small sample size.

Aguirre-Quifonero et al. (2019) conducted a single-center test validation study to evaluate the BD MAX™ vaginal panel for the diagnosis of bacterial vaginosis (BV), vulvovaginal candidiasis (VVC) and trichomoniasis and compared the test to conventional diagnostic methods. The study included 1,000 vaginal samples of women ≥ 14 years of age (median age 39 years) with 5% of the samples belonging to pregnant women. The authors reported that 19.3% of the samples were classified as BV while 33.6% were classified as VVC and 2.1% of the samples resulted in a diagnosis of *T. vaginalis*. The authors also reported that 43 of the 1000 (4.3%) samples analyzed were initially invalidated; however, after they were re-analyzed, 30.2% (13/43) remained invalidated whereas 69.8% (30/43) provided a valid result. There were three limitations of the study including the fact that vaginitis, especially VVC is often clinical diagnosed without laboratory confirmation, as such, microbiological analysis is only obtained when the patient does not recover following initial treatment. This may have resulted in the measurement of the burden of VVC being overestimated. Another limitation noted by the authors was the lack of information regarding prior treatment the participants may have received, and the third limitation was that the clinical outcomes for patients with discordant results were not evaluated. The authors concluded that the BD MAX vaginal panel was highly sensitive and specific and that it simplified the identification of infectious vaginitis.

Van Der Pol et al. (2019) conducted a non-matched, retrospective, multi-center study using de-identified residual specimens from the MVP clinical study to evaluate the likelihood of STIs (sexually transmitted infections) in women using a molecular diagnostic assay. The study included specimens from 581 adult women (median age 28.2 years, 23.9% white, 58% black) who previously provided specimens for the MVP study. Positivity rates were calculated for *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis* DNA, detected using the BD MAX CT/GC/TV (MCGT) assay. *Trichomonas vaginalis* results were consistent between the BD MAX CT/GC/TV assay and the BD MAX Vaginal Panel (MVP) assay in 559 of 560 samples. Concordance between the BD MAX CT/GC/TV assay and the BD MAX Vaginal Panel for detection of *T. vaginalis* was determined. Women with bacterial vaginosis alone or with concurrent *Candida* spp infections had high rates of coinfection with STIs (24.4%–25.7%); samples from women who were negative for vaginitis had substantially lower positivity rates (7.9%; $P < .001$). *Trichomonas vaginalis* results were consistent between the BD MAX CT/GC/TV assay and the BD MAX Vaginal Panel in 559 out of 560 samples. The authors concluded that the data suggested, as have other studies, that women with symptoms of vaginitis may be at risk for an STI. Regardless of the type of clinic in which patients are treated, molecular testing may provide broad diagnostic coverage for symptomatic women and improve the management of a patient's care. This study had 3 limitations. First, since the MCGT assay was performed on frozen remaining specimens, the specimens were tested beyond the stability period. Second, the samples were chosen to include all available TV-positive specimens, resulting in the distribution of TV in the study population was not completely representative of that previously published. Third, the statistical power for comparison of STI rates in vaginitis positive and negative groups for this pathogen was limited by the low numbers of GC-positive samples.

Schwebke et al. (2018) analyzed the BD MAX vaginal panel compared to reference for detection of BV, *Candida* spp., and TV. Specimens from 1,740 women were analyzed using the BD MAX panel. Clinician diagnosis (Amsel's test, KOH preparation, and wet mount) were also performed. All testing methods were compared to the respective reference methods. The BD MAX panel resulted in significantly higher sensitivity and negative predictive value than clinician diagnosis. In addition, this test showed a statistically higher overall percent agreement with each of the three reference methods than did clinician diagnosis. The authors concluded that findings from the current study supported the potential utility of the BD MAX vaginal panel in the differential diagnosis of vaginitis. The authors indicated that future studies are required to establish the benefits regarding the application of this investigational test in a practical setting.

Van Der Pol et al. (2017) conducted a comparative study with 2,114 women and 840 men to assess the performance of the BD Max CT/GC/TV Assay for combined chlamydia (CT), gonorrhea (GC), and trichomonas (TV) testing. Samples included endocervical swabs, vaginal swabs, and urine specimens. Testing for CT, GC, and TV included 1,143 women with an additional 847 tested for CT and GC only, for a total of 1,990 women. Positivity rates for CT, GC, and TV were 7.1%, 2.3% and 13.5%, respectively. For men, only urine specimens were used and TV performance was not evaluated. For the male specimens, 181/830 (21.8%) and 108/840 (12.9%) chlamydia and gonorrhea infections, respectively, were noted. Comparator assays included BD ProbeTec Chlamydia trachomatis Qx (CTQ)/Neisseria gonorrhoeae Qx (GCQ), Hologic Aptima Combo 2 (AC2) and Aptima TV (ATV), trichomonas microscopy, and culture. MAX CT sensitivity was 99.3%, 95.7%, 91.5%, and 96.1% for vaginal swabs, endocervical swabs, female urine samples, and male urine samples, respectively. MAX GC sensitivity was 95.5%, 95.5%, 95.7%, and 99.1% in the same order. MAX TV sensitivity was 96.1% for vaginal swabs, 93.4% for endocervical swabs, and 92.9% for female urine samples. Across all sample types, specificity for all organisms was $\geq 98.6\%$. Performance estimates for the BD MAX assays were concordant with estimates calculated for the comparator assays. The authors concluded that the availability of CT/GC/TV multiplexed assay on a benchtop instrument with a broad menu has the potential to aid in local sexually transmitted infection (STI) testing at smaller laboratories and has the potential to encourage expanded screening for these widespread infections. This study was limited by the fact that males were not tested for TV, and that some of the sample collections were done by the participants which may lead to variability in sample collection.

Clinical Utility: Impact on Patient Management and Interpretation of Results

Molecular panel tests can detect additional pathogens that were not detected in the past with conventional methods of testing. Positive results may not indicate current active infection, therefore, it is important to determine whether the detected organisms represent pathogens or colonizers that could not be detected before.

Prevalence

Hernández-Rosas et al. (2023) performed a prospective cross-sectional study to describe the prevalence of STIs and vaginosis in urogenital samples from patients who had been tested exclusively for HPV genotyping. The study included 408 females and males ages 20-80. Eligible participants had negative and positive HPV genotyping test results and agreed to early detection or had HPV antecedents. They provided the same urogenital samples used for HPV detection and, through their multiplex in-house PCR assay, they screened for Chlamydia trachomatis, Candida spp., Ureaplasma spp., Neisseria gonorrhoeae, Mycoplasma spp., molluscum contagiosum virus (MCV), Trichomonas vaginalis, herpes simplex virus 1 and 2 (HSV), Treponema pallidum, Staphylococcus aureus, Haemophilus spp., and Klebsiella spp. The subsequent statistical analysis aimed to show correlations between HPV genotypes and the identified pathogens. Out of the participants, 72.1% (n = 294) tested positive for HPV genotypes. HR-HPV (high-risk HPV) genotypes comprised 51 (8.1%), 66 (7.1%), and 58 (6.1%). Haemophilus spp., Ureaplasma spp., Candida spp., Staphylococcus aureus, and Mycoplasma spp. often co-occurred with HPV infection. Gender-based variations were notorious for Mycoplasma spp., Ureaplasma spp., and MCV. Coinfections were prevalent (43.9%), with a positive HPV result elevating the risk for Trichomonas vaginalis, Mycoplasma spp., Staphylococcus aureus, HSV, and MCV. HPV 16 correlated with Ureaplasma spp. and HSV, while HPV 6 was linked with MCV and HSV. Coinfections with HPV positive test for Trichomonas vaginalis was 0.2% (n = 1), Neisseria gonorrhoeae 0.7% (n=3), Chlamydia trachomatis 2.7% (n=11) and HSV 1/2 1.0% (n=4). The authors concluded there are significant coinfections, mainly Haemophilus spp 32.4% (n=132) and Ureaplasma spp. 24.8% (n=101), and associations between HPV genotypes and pathogens, emphasizing the importance of routine screening to explore clinical implications in urogenital health.

Lee et al. (2022) performed a prevalence study to analyze coinfections with sexually transmitted pathogens according to age in the Republic of Korea from 2018-2020. 65,191 samples of urine, swab, and other types submitted for STI screening were obtained from U2Bio Co. Ltd. (Seoul, Republic of Korea). Multiplex polymerase chain reaction was performed, which is a sensitive and rapid method for simultaneous detection of STIs caused by multiple different pathogens. Patients were tested for coinfections with 12 sexually transmitted pathogens: Candida albicans, Trichomonas vaginalis, Chlamydia trachomatis, HSV1, HSV2, Mycoplasma genitalium, Mycoplasma hominis, Gardnerella vaginalis, Neisseria gonorrhoeae, Treponema pallidum, Ureaplasma parvum, and Ureaplasma urealyticum. Out of the 65,191 samples tested, 35,366 (54.3%) tested positive for one or more sexually transmitted pathogens. The prevalence of coinfections with two or more sexually transmitted pathogens was inversely proportional to age. The average age of patients coinfecting with two types of pathogens was 36, and the age of the individual coinfecting with nine types of pathogens was 19. The rates of coinfection with sexually transmitted pathogens and age distribution also differed according to sex and the sexually transmitted pathogen type. Coinfections in male patients were more frequent in the 30-39 year age group, whereas the age of female patients with coinfections varied from 19-40 years. Patients with N. gonorrhoeae and C. trachomatis infection had a low rate of coinfection, whereas those infected with M. hominis and T. vaginalis had a high rate of coinfection with other sexually transmitted pathogens. In a study conducted at an STI clinic in Birmingham, Alabama, USA, coinfection with M. genitalium in women with C. trachomatis was found to be uncommon. It

was present in only 7.3% of the cofection patients. A study of pregnant women who visited a hospital in Ghana revealed that *Candida* (53%) coinfection was common in women with *T. vaginalis* infection. In another study from Iran where coinfection with sexually transmitted pathogens was confirmed using mPCR, 10/300 patients (3.3%) tested had confirmed coinfections, including 3 cases of *C. trachomatis*/*T. vaginalis*, 2 cases of *C. trachomatis*/*N. gonorrhoeae*, and 5 cases of *N. gonorrhoeae*/*T. vaginalis* coinfections. In a study conducted in Beijing, China, among the patients with coinfections, 60.6% of men and 71.4% of women were coinfecting with *U. urealyticum* and *C. trachomatis*. Limitations of the study included that it was not possible to determine the characteristics of sexual partners. Another limitation was that this was a retrospective study that used lab records and no data on clinical characteristics of the patients. The authors concluded that a substantial proportion of patients with STIs are coinfecting with multiple pathogens.

References

- Aguirre-Quiñonero A, Castillo-Sedano IS, Calvo-Muro F, et al. Accuracy of the BD MAX™ vaginal panel in the diagnosis of infectious vaginitis. *Eur J Clin Microbiol Infect Dis.* 2019;38(5):877-882.
- Dien Bard J, McElvania E. Panels and syndromic testing in clinical microbiology. *Clin Lab Med.* 2020;40(4):393-420.
- Ginocchio CC, Chapin K, Smith JS, et al. Prevalence of trichomonas vaginalis and coinfection with chlamydia trachomatis and neisseria gonorrhoeae in the United States as determined by the Aptima trichomonas vaginalis nucleic acid amplification assay. *J Clin Microbiol.* 2012;50(8):2601-2608.
- Hernández-Rosas F, Rey-Barrera M, Hernández-Barajas F, et al. Unveiling Hidden Risks: Intentional Molecular Screening for Sexually Transmitted Infections and Vaginosis Pathogens in Patients Who Have Been Exclusively Tested for Human Papillomavirus Genotyping. *Microorganisms.* 2023 Oct 30;11(11):2661.
- Kreisel KM, Weston EJ, St Cyr SB, et al. Estimates of the prevalence and incidence of chlamydia and gonorrhea among US men and women, 2018. *Sex Transm Dis.* 2021;48(4):222-231.
- Lee SJ, Jang TS, Jeon JS, et al. Coinfections with multiple sexually transmitted pathogens in Republic of Korea, 2018-2020. *J Clin Lab Anal.* 2022 Oct;36(10):e24682.
- Nyirjesy P, Banker WM, Bonus TM. Physician awareness and adherence to clinical practice guidelines in the diagnosis of vaginitis patients: a retrospective chart review. *Popul Health Manag.* 2020;23(S1):S13-S21.
- Ramanan P, Bryson AL, Binnicker MJ, Pritt BS, Patel R. Syndromic panel-based testing in clinical microbiology. *Clin Microbiol Rev.* 2017;31(1):e00024-17.
- Schwebke JR, Gaydos CA, Nyirjesy P, et al. Diagnostic performance of a molecular test versus clinician assessment of vaginitis. *J Clin Microbiol.* 2018;56(6):e00252-18.
- Schwebke JR, Taylor SN, Ackerman R, et al. Clinical validation of the Aptima bacterial vaginosis and Aptima candida/trichomonas vaginitis assays: results from a prospective multicenter clinical study. *J Clin Microbiol.* 2020;58(2):e01643-19.
- Thompson A, Timm K, Borders N, et al. Diagnostic performance of two molecular assays for the detection of vaginitis in symptomatic women. *Eur J Clin Microbiol Infect Dis.* 2020;39(1):39-44.
- Van Der Pol B, Daniel G, Kodsi S, et al. Molecular-based testing for sexually transmitted infections using samples previously collected for vaginitis diagnosis. *Clin Infect Dis.* 2019;68(3):375-381.
- Van Der Pol B, Williams JA, Fuller D, et al. Combined testing for chlamydia, gonorrhea, and trichomonas by use of the BD Max CT/GC/TV assay with genitourinary specimen types. *J Clin Microbiol.* 2017;55(1):155-164.

Policy History/Revision Information

Date	Summary of Changes
10/01/2024	<p>Coverage Rationale CMS Local Coverage Determinations (LCDs) and Articles</p> <ul style="list-style-type: none"> Added instruction to refer to the coverage rationale [listed in the policy] for coverage guidelines for states/territories with no Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs) <p>Centers for Medicare & Medicaid (CMS) Related Documents</p> <ul style="list-style-type: none"> Added notation to indicate for the state of Virginia: Part B services for the city of Alexandria and the counties of Arlington and Fairfax are excluded for the Palmetto GBA jurisdiction and included within the Novitas Solutions, Inc. jurisdiction

Date	Summary of Changes
	<p>Supporting Information</p> <ul style="list-style-type: none"> Archived previous policy version MMP373.29

Instructions for Use

The Medicare Advantage Policy documents are generally used to support UnitedHealthcare coverage decisions. It is expected providers retain or have access to appropriate documentation when requested to support coverage. This document may be used as a guide to help determine applicable:

- Medical necessity coverage guidelines; including documentation requirements, and/or
- Medicare coding or billing requirements.

Medicare Advantage Policies are applicable to UnitedHealthcare Medicare Advantage Plans offered by UnitedHealthcare and its affiliates. This Policy is provided for informational purposes and does not constitute medical advice. It is intended to serve only as a general reference and is not intended to address every aspect of a clinical situation. Physicians and patients should not rely on this information in making health care decisions. Physicians and patients must exercise their independent clinical discretion and judgment in determining care. Treating physicians and healthcare providers are solely responsible for determining what care to provide to their patients. Members should always consult their physician before making any decisions about medical care.

Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The member specific benefit plan document identifies which services are covered, which are excluded, and which are subject to limitations. In the event of a conflict, the member specific benefit plan document supersedes this policy. For more information on a specific member's benefit coverage, please call the customer service number on the back of the member ID card or refer to the [Administrative Guide](#).

Medicare Advantage Policies are developed as needed, are regularly reviewed, and updated, and are subject to change. They represent a portion of the resources used to support UnitedHealthcare coverage decision making. UnitedHealthcare may modify these Policies at any time by publishing a new version on this website. Medicare source materials used to develop these policies may include, but are not limited to, CMS statutes, regulations, National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and manuals. This document is not a replacement for the Medicare source materials that outline Medicare coverage requirements. The information presented in this Policy is believed to be accurate and current as of the date of publication. Where there is a conflict between this document and Medicare source materials, the Medicare source materials apply. Medicare Advantage Policies are the property of UnitedHealthcare. Unauthorized copying, use, and distribution of this information are strictly prohibited.

UnitedHealthcare follows Medicare coverage guidelines found in statutes, regulations, NCDs, and LCDs to determine coverage. The clinical coverage criteria governing certain items or services referenced in this Medical Policy have not been fully established in applicable Medicare guidelines because there is an absence of any applicable Medicare statutes, regulations, NCDs, or LCDs setting forth coverage criteria and/or the applicable NCDs or LCDs include flexibility that explicitly allows for coverage in circumstances beyond the specific indications that are listed in an NCD or LCD. As a result, in these circumstances, UnitedHealthcare applies internal coverage criteria as referenced in this Medical Policy. The internal coverage criteria in this Medical Policy was developed through an evaluation of the current relevant clinical evidence in acceptable clinical literature and/or widely used treatment guidelines. UnitedHealthcare evaluated the evidence to determine whether it was of sufficient quality to support a finding that the items or services discussed in the policy might, under certain circumstances, be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.

Providers are responsible for submission of accurate claims. Medicare Advantage Policies are intended to ensure that coverage decisions are made accurately. UnitedHealthcare Medicare Advantage Policies use Current Procedural Terminology (CPT®), Centers for Medicare and Medicaid Services (CMS), or other coding guidelines. References to CPT® or other sources are for definitional purposes only and do not imply any right to reimbursement or guarantee claims payment.

For members in UnitedHealthcare Medicare Advantage plans where a delegate manages utilization management and prior authorization requirements, the delegate's requirements need to be followed.